Cargando…

Clinical experience with ferric carboxymaltose in the management of anemia in acute gastrointestinal bleeding

OBJECTIVE: The aim of this study was to assess the efficacy and safety of intravenous ferric carboxymaltose (FCM) following hospitalization for acute gastrointestinal bleeding (AGIB) in the context of a restrictive transfusion strategy. PATIENTS AND METHODS: A retrospective single-center study analy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ballester-Clau, Raquel, Torres Vicente, Gisela, Voltà-Pardo, Tania, López-Barroso, Laura, Cucala-Ramos, Mercedes, Reñé-Espinet, Josep M., Planella de Rubinat, Montse
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams And Wilkins 2019
Materias:	Original Articles: Gastroenterology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282679/ https://www.ncbi.nlm.nih.gov/pubmed/30335628 http://dx.doi.org/10.1097/MEG.0000000000001282

Ejemplares similares

Efficacy and Safety of Treatment With Ferric Carboxymaltose in Patients With Cirrhosis and Gastrointestinal Bleeding
por: Ballester-Clau, Raquel, et al.
Publicado: (2020)

Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia
por: Calleja, José Luis, et al.
Publicado: (2015)

Intravenous ferric carboxymaltose for the treatment of iron deficiency anemia
por: Friedrisch, João Ricardo, et al.
Publicado: (2015)

Ferric Carboxymaltose as Treatment in Women with Iron-Deficiency Anemia
por: Seid, Melvin H., et al.
Publicado: (2017)

Ferric carboxymaltose for treatment of iron deficiency and iron deficiency anemia caused by abnormal uterine bleeding
por: Hagras, Ahmed M., et al.
Publicado: (2022)

Intravenous ferric carboxymaltose versus oral ferrous sulfate replacement in elderly patients after acute non-variceal gastrointestinal bleeding (FIERCE): protocol of a multicentre, open-label, randomised controlled trial
por: Teutsch, Brigitta, et al.
Publicado: (2023)

Ferric carboxymaltose: A revolution in the treatment of postpartum anemia in Indian women
por: Rathod, Setu, et al.
Publicado: (2015)

Intravenous ferric carboxymaltose for the treatment of iron deficiency anemia: Letter to Editor
por: Kanshaiym, Sakiyeva, et al.
Publicado: (2020)

Efficacy of ferric carboxymaltose in iron deficiency anemia patients scheduled for pancreaticoduodenectomy
por: Park, Jangho, et al.
Publicado: (2023)

Optimizing iron delivery in the management of anemia: patient considerations and the role of ferric carboxymaltose
por: Toblli, Jorge Eduardo, et al.
Publicado: (2014)

Treatment of iron deficiency and iron deficiency anemia with intravenous ferric carboxymaltose in pregnancy
por: Froessler, Bernd, et al.
Publicado: (2018)

Safety, pharmacokinetics, and pharmacodynamics of intravenous ferric carboxymaltose in children with iron deficiency anemia
por: Korczowski, Bartosz, et al.
Publicado: (2023)

Intravenous ferric carboxymaltose for anaemia in pregnancy
por: Froessler, Bernd, et al.
Publicado: (2014)

Hypophosphatemia in children treated with ferric carboxymaltose
por: Posod, Anna, et al.
Publicado: (2020)

Assessing the costs and benefits of perioperative iron deficiency anemia management with ferric carboxymaltose in Germany
por: Froessler, Bernd, et al.
Publicado: (2018)

Iron Deficiency Anemia with Menorrhagia: Ferric Carboxymaltose a Safer Alternative to Blood Transfusion
por: Mishra, Vineet, et al.
Publicado: (2018)

Economic Evaluation of Ferric Carboxymaltose for the Management of Hemodialysis Patients with Iron Deficiency Anemia in Italy
por: Rognoni, Carla, et al.
Publicado: (2019)

MON-338 Severe Hypophosphatemia Induced by Intravenous Ferric Carboxymaltose Therapy for Iron Deficiency Anemia
por: Tam, Matthew, et al.
Publicado: (2020)

Ferric Carboxymaltose and Erythropoiesis-Stimulating Agent Treatment Reduces the Rate of Blood Transfusion in Refractory Anemia
por: Gidaro, Antonio, et al.
Publicado: (2022)

Ferric carboxymaltose for anemia in Crohn’s disease patients at a tertiary center: A retrospective observational cohort study
por: Siqueira, Natália Souza Nunes, et al.
Publicado: (2023)

Symptomatic severe hypophosphatemia after intravenous ferric carboxymaltose
por: Fang, Wendy, et al.
Publicado: (2019)

Direct Comparison of the Safety and Efficacy of Ferric Carboxymaltose versus Iron Dextran in Patients with Iron Deficiency Anemia
por: Hussain, Iftikhar, et al.
Publicado: (2013)

Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: A randomized trial
por: Adkinson, N. Franklin, et al.
Publicado: (2018)

Treatment of anemia in cancer patients undergoing chemotherapy with intravenous ferric carboxymaltose without erythropoiesis-stimulating agents
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2020)

Successful Treatment of Iron Deficiency Anemia with Ferric Carboxymaltose in an Elderly Patient with Multiple Comorbidities and COVID-19
por: Bassi, Vincenzo, et al.
Publicado: (2021)

An Economic Analysis of Ferric Derisomaltose versus Ferric Carboxymaltose in the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease in Norway, Sweden, and Finland
por: Pollock, Richard F, et al.
Publicado: (2021)

Cost-utility of ferric carboxymaltose (Ferinject®) for iron-deficiency anemia patients with chronic heart failure in South Korea
por: Lim, Eun-A, et al.
Publicado: (2014)

Comparison of ferric Carboxymaltose and iron sucrose complex for treatment of iron deficiency anemia in pregnancy- randomised controlled trial
por: Jose, Ambily, et al.
Publicado: (2019)

Improved Hemoglobin Response with Ferric Carboxymaltose in Patients with Gastrointestinal-Related Iron-Deficiency Anemia Versus Oral Iron
por: Lichtenstein, Gary R., et al.
Publicado: (2018)

Evaluation of Minimal Optimal Dose of Intravenous Ferric Carboxymaltose for Treatment of Iron Deficiency Anemia and Risk of Transient Hyperferritinemia
por: Alharbi, Ahmad A, et al.
Publicado: (2022)

Patient-Reported Outcomes After Ferric Carboxymaltose Treatment for Iron Deficiency Anemia: A Prospective Observational Study
por: Kwong, Winghan J, et al.
Publicado: (2023)

Seven-Year Single-Center Experience of the Efficacy and Safety of Ferric Carboxymaltose in Cancer Patients with Iron-Deficiency Anemia
por: Aktaş, Burak Yasin, et al.
Publicado: (2023)

Intravenous ferric carboxymaltose for the treatment of iron deficiency anaemia – reply
por: Cancado, Rodolfo Delfini, et al.
Publicado: (2020)

The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study
por: Ponikowski, Piotr, et al.
Publicado: (2015)

Safety and effectiveness of ferric carboxymaltose intravenous therapy in pediatric patients with chronic kidney disease
por: Garcia-Ortega, Patricia, et al.
Publicado: (2022)

Effectiveness and safety of ferric carboxymaltose therapy in peritoneal dialysis patients: an observational study
por: Portolés-Pérez, Jose, et al.
Publicado: (2019)

High-Dose Intravenous Iron with Either Ferric Carboxymaltose or Ferric Derisomaltose: A Benefit-Risk Assessment
por: Boots, Johannes M. M., et al.
Publicado: (2022)

Intravenous ferric carboxymaltose and ferric derisomaltose alter the intestinal microbiome in female iron-deficient anemic mice
por: Rieg, Timo, et al.
Publicado: (2023)

Impact of intravenous ferric carboxymaltose on heart failure with preserved and reduced ejection fraction
por: López‐Vilella, Raquel, et al.
Publicado: (2021)

Safety and Efficacy of Intravenous Ferric Carboxymaltose (750 mg) in the Treatment of Iron Deficiency Anemia: Two Randomized, Controlled Trials
por: Barish, Charles F., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_u36qvrne3grs59vtfkkpkeb8et